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Background: The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic
factor in acute lymphocytic leukemia (ALL). This study was to identify serum candidate peptides for monitoring
MRD in adult ALL.
Results: A total of 33 peptides in the molecular weight range of 1000-10000 Da were detected using ClinProt
system and statistically different between adult patients with ALL and healthy controls. Quick classifier (QC) algorithm
was used to obtain a diagnostic model consisting of five peptides that could discriminate patients with ALL from
controls with a high sensitivity (100%) and specificity (96.67%). The peptides in the QC model were identified as fibrinogen
alpha chain (FGA), glutathione S-transferase P1 (GSTP1), isoform 1 of fibrinogen alpha chain precursor, platelet factor 4
(PF4) by high pressure/performance liquid chromatography mass spectrometry/mass spectrometry. Relative intensities of
the five peptides were compared among ALL different groups for the potential importance of MRD evaluation in ALL.
The peptides with increased relative intensities in newly diagnosed (ND) ALL patients were found to be decreased in their
relative intensities after complete remission (CR) of adult ALL. When ALL patients were refractory & relapsed (RR), relative
intensities of the peptides were elevated again. Peptides with decreased relative intensities in ND and RR ALL patients
were found to be increased in their relative intensities when ALL patients achieved CR. The findings were validated by
ELISA and western blot. Further linear regression analyses were performed to eliminate the influence of platelet and white
blood cell counts on serum protein contents and indicated that there were no correlations between the contents of all
four proteins (PF4, connective tissue active peptide III, FGA and GSTP1) and white blood cell or platelet counts in ALL
different groups and healthy control.
Conclusions: We speculate the five peptides, FGA, isoform 1 of fibrinogen alpha chain precursor, GSTP1, PF4 and
connective tissue active peptide III would be potential biomarkers for forecasting relapse, monitoring MRD and evaluating
therapeutic response in adult ALL.
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Acute lymphocytic leukemia (ALL) is a hematological
malignancy with high heterogeneity. Adult ALL patients
with different immunophenotypic, cytogenetic and
molecular abnormalities manifest distinct prognostic
and therapeutic implications [1,2]. Considerable progress
has been made in the therapeutics of ALL during the
past two decades, however, the 5-year overall survival
rates of adult ALL are within the 30-40% range, despite
complete remission (CR) exceeding 90% in contemporary
treatment series [3]. The poor outcome of most adult ALL
is due to an inevitable relapse after induction chemotherapy.
Leukemia relapse is thought to result from minimal residual
disease (MRD). MRD is the residual leukemia cells (as many
as 108-9) that remain following achievement of morphologic
remission and are below the limits of detection using
conventional microscopic and cytogenetic assessment
of the bone marrow [4]. MRD status best discriminated
outcome after Phase 2 induction, when the relative risk of
relapse was 8.95-fold higher in MRD-positive (≥10-4)
patients and the 5-year relapse free survival was 15%
compared to 71% in MRD-negative (<10-4) patients [5-7].
Because MRD is an independent prognostic factor for
relapse and survival of adult ALL, postremission MRD
monitoring is now used to predict an impending relapse
and to start preemptive salvage treatment in time [8,9].
Current methodologies to monitor MRD in ALL
include flow cytometry (FCM) detection of aberrant
immunophenotypes, which can detect 1 leukemic cell
among 10000 normal cells (0.01%), and real-time
polymerase chain reaction (RT-PCR) amplification of fusion
transcripts, T-cell receptor (TCR) and immunoglobulin (Ig)
genes, which has a sensitivity of 0.001% [8-10]. However, all
of the methods mentioned above have some limitations.
First, a potential pitfall of FCM results from similarities
between leukemic lymphoblasts and nonmalignant lymph-
oid precursors in various phases of regeneration or
chemotherapy-induced alterations (phenotypic shifts)
that may lead to false positivity. Moreover, FCM data
interpretation requires a high level of expertise. Second,
most adult ALL patients lack specific chromosome
aberrations. Thus, RT-PCR amplification of fusion genes is
currently limited to Philadelphia chromosome-positive
(Ph+) ALL. Uncertain quantification, false-positivity result-
ing from cross-contamination, and false-negativity from
RNA instability are caveats affecting fusion genes detect-
ing. RT-PCR amplification of Ig and TCR genes are la-
borious and costly, because reagents for these types of
assays are patient-specific. Furthermore, PCR analyses of
Ig and TCR gene rearrangements need experienced
personnel and standardization. In addition, oligoclonality
and clonal evolution may produce false-negative results
[4,6,11,12]. Third, bone marrow cells are the specimens of
FCM and RT-PCR based MRD monitoring. Bone marrowaspiration is invasive and increases the patients’ pain,
whereas venepuncture is readily accepted by patients.
Serum is easily accessible and contains a treasure trove of
previously unstudied biomarkers that could reflect the on-
going physiologic or pathologic state of all tissues [13].
Therefore, blood becomes one of the best sources for bio-
markers researching.
The low-molecular-weight (LMW) region of the blood
proteome, which is a mixture of small intact proteins
plus fragments of the large proteins, is a treasure trove
of diagnostic information ready to be harvested by
nanotechnology [13]. Serum peptidome refers to serum
protein fragments and peptides whose molecular weights
are less than 20 kDa, particularly those of LMW [14]. In
recent years, mass spectrometry-based serum peptide
profiling has been widely applied in the studies of
markers in solid tumors [15,16]. Preliminary findings
showed that a group of serum peptides could be used for
disease diagnosis and predicting disease progression.
Several serum peptidome researches on hematological
malignancies had also been carried out. For instance,
Albitar’s group explored the potential of peptidomic
analysis of peripheral blood plasma, using ProteinChip-
surface enhanced laser desorption ionization time of flight
mass spectrometry (SELDI-TOF-MS) to predict recurrence
of adult ALL, with correct predictions 84% to 92%
[17]. A classification model constructed by ProteinChip-
SELDI-TOF-MS could discriminate the pediatric ALL
samples from the controls with a sensitivity of 91.8% and
a specificity of 90.0%. Furthermore, platelet factor (PF4),
connective tissue activating peptide III (CTAP-III) and
two fragments of C3a were identified by high pressure/
performance liquid chromatography mass spectrometry/
mass spectrometry (HPLC-MS/MS). They may be potential
biomarkers to distinguish pediatric ALL patients from
healthy controls (HCs) and pediatric acute myeloid leukemia
(AML) patients [18]. ProteinChip-SELDI-TOF-MS had the
shortcoming of lower resolution and the peptides of interest
could not be eluted for further identification [19]. In recent
years, magnetic beads with large separation capacity
have replaced ProteinChip for sample preparation and
enrichment. Because magnetic beads are high-throughput,
simple and quick to operate, beads based-ClinProt
technology has been widely used in the researches of
serum peptidome in solid tumors [20-24]. Previously, our
group established a Quick classifier (QC) diagnostic model
by ClinProt system, with a high sensitivity and specificity
to discriminate adult AML patients from HCs. The
three peptides were identified as ubiquitin-like modifier
activating enzyme 1 (UBA1), isoform 1 of fibrinogen alpha
chain precursor and PF4. Relative intensities of the three
peptides were correlated with remission and clinical
outcome of adult AML patients [25]. Using the ClinProt
system, a Supervised Neural Network Algorithm (SNN)
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diagnosed (ND) multiple myeloma from HCs [26].
In our study, a comparative peptidomics method combin-
ing weak cation exchange beads (MB-WCX) and matrix
assisted laser desorption ionization time of flight mass spec-
trometry (MALDI-TOF-MS) were used to analyze serum
peptide profiles of adult ALL patients in ND group, CR
group, refractory & relapsed (RR) group and HC group. We
hypothesized that ClinProt-based serum peptidomics could
detect differentially expressed peptides among different
groups of adult ALL. Differences in peptides expression are
reported in serum and bone marrow cells of ALL different
groups and HC group. Moreover, differences in peptides
expression are correlated with ALL therapeutic response
and the time point of ALL relapse. These results suggest that
the differentially expressed peptides would be appropriately
adapted for predicting relapse, monitoring MRD and evalu-
ating therapeutic response of adult ALL in clinical practice.
Results
Serum peptide fingerprints comparison between newly
diagnosed ALL and healthy control
Despite varying peptide masses and spectrum intensities,
the peak coefficient of variations (CVs) were all <14% in
the within-run assays and <22% in the between-run
assays. The CV value of the relative intensity of each
peak in MALDI-TOF-MS was less than 30%, indicat-
ing that ClinProt system had good repeatability [25].
To screen serum peptides of interest for adult ALL,
comparative analyses of serum peptide fingerprints
were performed between adult ALL patients and HCs
by ClinProtools2.2 software. It was shown that peak
number and intensity in serum peptide fingerprints of
ND ALL patients were completely different from that
of HCs (Figure 1). A total of 33 peptide peaks in the
molecular weight range of 1000-10000 Da were
significantly different between the two groups (p < 0.05).
In ALL ND group, 13 peptides were up-regulated and
20 were down-regulated comparing with healthy controls
(Table 1).
Establishment of QC diagnostic model and blind
verification
Genetic algorithm (GA), SNN and QC embedded in
ClinProtools2.2 software were used to establish cross-
validated classification model for distinguishing adult ALL
from HCs. Among them, the QC model was composed of
five peptides and had optimal distinction efficiency, in the
training set with a sensitivity of 100% and a specificity of
96.67%.
In the QC model, comparing with healthy controls, pep-
tides with molecular weight of 2661.27 Da and 2991.46 Da
were upregulated in ALL ND group (Figure 2A, B), pep-
tides with molecular weight of 3443.92 Da, 7764.29 Daand 9288.31 Da were downregulated (Figure 2C, D, E).
Blind verification showed that the QC model could
correctly identify 52 cases out of total 54 ALL cases and
53 healthy cases from 55 HCs.
The diagnostic capability of each peak determined by
the receiver operating characteristic (ROC) curve is
reported in Figure 3. Areas under the curve (AUCs) of
the peptides in the QC model were 92.56%, 89.22%, 91%,
86.56% and 90.22%, respectively. Generally, it is believed
that the model has lower diagnostic value when AUC ≤ 0.7,
moderate diagnostic value when 0.7 <AUC ≤ 0.9, and higher
diagnostic value when AUC> 0.9. The AUCs of three
peptide peaks in the QC diagnostic model were greater than
0.9, and the AUCs of the other two peaks were less than
0.9, but very close to 0.9.These results indicated that
the QC diagnostic model composed of five peptides
could distinguish the ND adult ALL from HCs.Peptides identification
The peptides in the QC model were purified and identified
by HPLC-MS/MS. Data analysis software BioworksBrowser
3.3.1 SP1 was applied for Sequest™ searching. Positive
protein identification was accepted for a peptide with Xcorr
of greater than or equal to 3.50 for triply charged ions and
2.5 for doubly charged ions, and all with ΔCn ≥ 0.1, peptide
probability ≤ 1e-3. Peptides with molecular weight of
2661.27 Da, 2991.46 Da, 3443.92 Da and 7764.29 Da were
identified as peptide fragments of fibrinogen alpha chain,
glutathione S-transferase P1, isoform 1 of fibrinogen alpha
chain precursor 1 and platelet factor 4 (Table 2, Figures 4,
5, 6 and 7). However, peptide with molecular weight of
9288.31 Da was not identified because of high molecular
weight. Literature review suggested that it might be the
connective tissue active peptide III [18,27].Relative intensities of the five peptides in QC model in
ALL different groups
In order to explore the potential clinical significance of
the five peptides (components of the QC diagnostic
model), we compared the relative intensities of the five
peptides among ALL ND group, CR group, RR group
and HC group (detail data were showed in Table 3).
Kruskal-Wallis rank sum test was performed to ascertain
the significant level of difference among the groups.
Compared with HC group and CR group, the relative
intensities of peptides with molecular weight of
2661.27 Da and 2991.46 Da were significantly elevated
in ALL ND group (p < 0.001, p < 0.001) and RR group
(p < 0.001, p < 0.001). No significant differences were
observed in the relative intensities of peptides with
molecular weight of 2661.27 Da and 2991.46 Da between
the ND group and the RR group (p = 0.76, p = 0.59) nor
the HC group and the CR group (p = 0.67, p = 0.38).
Figure 1 Serum peptide fingerprints and cluster analysis of newly diagnosed ALL and healthy control. A. Comparison of serum peptide
fingerprints between ALL patients and healthy controls showed that peak number and intensity of the two groups were completely different.
B. Stack view of comparison between ALL patients and healthy controls. (Red: ALL newly diagnosed group Green: Healthy control group).
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with molecular weight of 3443.92 Da, 7764.29 Da and
9288.31 Da were found in ND group and RR group,
compared with HC group (p < 0.001, p < 0.001, p < 0.001)
and CR group (p < 0.001, p < 0.001, p < 0.001). No signifi-
cant differences were observed in the relative intensities of
peptides with molecular weight of 3443.92 Da, 7764.29 Da
and 9288.31 Da between the ND group and the RR group
(p = 0.62, p = 0.75, p = 0.26) nor the HC group and the CR
group (p = 0.71, p = 0.23, p = 0.67).
To define the threshold for each peptide that could be
used to discriminate CR and RR patients, ROC analysis wasperformed. The cutoff values of the relative intensities of
the five peptides were 8.06, 4.87, 1.75, 2.02 and 1.42,
respectively (Additional file 1: Figure S1).
In addition, we tested whether the relative intensities
of the five peptides were correlated with subtypes, gender
or age in ND ALL patients. The results showed that the
relative intensities of the five peptides were not different
between B-ALL and T-ALL (p > 0.05). It is important to
point out that no statistical differences were observed in
relative intensities of the five peptides when ND ALL
patients were classified into two groups according to gender
or age (p > 0.05, p > 0.05) (Additional file 2: Table S1).
Table 1 Different expressed peptides between newly diagnosed ALL and healthy controls
Index Mass Dave PWKW Ave1 Ave2 StdDev1 StdDev2 Expression Change
61 9288.31 2.32 < 0.000001 1.31 3.63 0.28 1.87 ↓
27 3443.92 1.1 < 0.000001 1.54 2.64 0.66 0.9 ↓
41 4249.06 0.76 0.000007 1.7 2.46 0.62 0.49 ↓
13 2661.27 20.95 < 0.000001 28.39 7.44 22.56 3.69 ↑
43 4645.31 1.74 0.00000373 1.67 3.41 1.09 1.75 ↓
7 1945.51 1.06 0.00000114 2.01 3.06 0.39 1.12 ↓
8 2093.83 1.15 0.0000791 3.38 2.23 1.38 0.44 ↑
33 4072.42 0.4 0.00175 1.59 1.99 0.43 0.4 ↓
35 4108.67 0.45 0.00129 1.66 2.1 0.53 0.41 ↓
28 3884.26 0.85 0.000281 1.65 2.5 0.82 1.02 ↓
4 1546.94 5.98 0.000942 10.48 4.5 8.72 2.57 ↑
12 2644.19 0.86 0.001 2.93 2.07 1.23 0.5 ↑
36 4123.33 0.42 0.00445 1.7 2.13 0.54 0.43 ↓
62 9367.9 1.28 0.0108 0.95 2.23 0.41 1.2 ↓
11 2561.9 1.28 0.000009 3.07 1.79 1.97 0.49 ↑
21 2991.46 5.28 < 0.000001 17.24 1.96 8.54 0.63 ↑
34 4091.61 1.46 0.00622 3.16 4.62 1.55 1.93 ↓
58 7764.29 1.3 0.00000217 1.39 2.68 0.7 1.44 ↓
10 2545.82 0.92 0.00619 2.98 2.06 1.53 0.47 ↑
46 5064.98 0.33 0.0374 1.11 1.44 0.27 0.53 ↓
2 1466.84 5.01 0.000639 8.46 3.46 4.84 2.44 ↑
1 1450.14 1 0.0163 4.09 3.1 1.72 0.68 ↑
57 7025.82 0.69 0.00913 0.83 1.52 0.35 1.23 ↓
14 2673.64 1.7 0.00626 4.04 2.34 1.22 0.53 ↑
42 4266.78 1 0.0154 2.56 3.57 1.22 1.6 ↓
18 2900.77 0.89 0.0288 2.62 1.74 1.71 0.48 ↑
5 1618.2 3.56 0.0000421 6.76 3.19 4.43 1.65 ↑
3 1526.98 1.92 0.0107 4.29 2.37 2.03 0.61 ↑
38 4169.26 0.43 0.0146 2.04 2.46 0.81 0.54 ↓
39 4194.35 0.71 0.0173 2.88 3.59 1.35 1.01 ↓
29 3891.28 0.44 0.0285 1.83 0.77 0.86 0.17 ↓
22 3192.79 0.38 0.00906 2.03 2.4 1.19 0.78 ↓
25 3263.65 0.84 0.00446 2.98 3.82 1.7 1.75 ↓
Index: Peptide peak index; Mass: Mass to charge ratio value; Dave: Differences of average peak intensity between newly diagnosed ALL group and healthy control
group; P value: p value of Wilcoxon test; Ave1: Average peak intensity of newly diagnosed ALL group; Ave2: Average peak intensity of healthy control group;
StdDev1: Standard deviation of the peak intensity average of newly diagnosed ALL group; StdDev2: Standard deviation of the peak intensity average of healthy
control group.
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relapse
During the follow-up, 39 newly diagnosed ALL patients
underwent relapse ultimately. The median relapse time
was 16 months (range 5-29 months) after initial diagnosis.
Our analyses included patients who relapsed very early
(during first 18 months after initial diagnosis: 56.4%, 22/39)
and early (between 18 and 30 months: 43.6%, 17/39),
whereas late relapse patients (>30 months) were absent.Correlation plots between the peak intensities of the five
peptides and the relapse time (months) were drawn. The
relative intensities of peptides with molecular weight of
2661.27 Da and 3443.92 Da were not correlated with
time point of ALL relapse. Correlation coefficients
were 0.115 (p = 0.347) and 0.071 (p = 0.666) (Figure 8A, C).
The relative intensities of peptides with molecular weight
of 2991.46 Da, 7764.29 Da and 9288.31 Da were correlated
with time point of ALL relapse. Correlation coefficients
Figure 2 Relative intensities comparisons of peptides from representative samples of ND ALL and HC. A. Upregulation of the peptide
with MW of 2661.27 Da in ALL ND group. B. Upregulation of the peptide with MW of 2991.46 Da in ALL ND group. C. Downregulation of the
peptide with MW of 3443.92 Da in ALL ND group. D. Downregulation of the peptide with MW of 7764.29 Da in ALL ND group. E. Downregulation of
the peptide with MW of 9288.31 Da in ALL ND group. (ND: newly diagnosed; HC: healthy control; MW: molecular weight). (Red: ALL newly diagnosed
group Green: Healthy control group).
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(Figure 8B, D, E).
Validation of protein fragments by immunoblotting
The levels of FGA, GSTP1 and PF4 protein in ALL and
control samples were determined by western blot analysis.
The levels of FGA and GSTP1 protein differed among the
leukemia cells in distinct ALL groups and normal cells by
immunoblotting (Figure 9A). Quantification of bands
from western blot analysis showed significantly increased
levels of FGA and GSTP1 protein in ND and RR ALL
samples, when compared with age-matched control and
CR ALL samples (p = 0.0049, p = 0.0012, Figure 9B, C).
Weak PF4 immunoreactive bands were seen in ND and
RR ALL cases (Figure 8A). Relative to age-matched CR
ALL and healthy control samples, quantification of bands
from western blot analysis showed significantly decreased
levels of PF4 in ND and RR ALL samples (p = 0.0061,
Figure 9D).
Determination of serum proteins by ELISA
Serum FGA, GSTP1, PF4 and CTAP-III contents were
detected by enzyme linked immunosorbent assay (ELISA)
in 40 ALL-ND, 40 ALL-CR, 40 ALL-RR patients and
40 HCs. FGA and GSTP1 contents in ALL-ND groupFigure 3 The diagnostic capability of each peak in QC model determi
with MW of 2661.27 Da is 92.56%, representing higher diagnostic value. B.A
moderate diagnostic value. C. AUC of the peptide with MW of 3443.92 Da
with MW of 7764.29 Da is 86.56%, representing moderate diagnostic value.
higher diagnostic value.(263.48 ± 70.19 μg/L, 78.62 ± 21.73 μg/L) and ALL-RR
group (268.92 ± 71.51 μg/L, 80.57 ± 22.15 μg/L) were
significantly increased (p = 2.8641E-7, p = 3.1879E-5;
p = 1.9692E-7, p = 3.3821E-5), compared with HC group
(30.44 ± 12.15 μg/L, 10.82 ± 2.31 μg/L) and CR group
(32.76 ± 13.28 μg/L, 11.31 ± 2.79 μg/L). Differences of the
platelet and white blood cell (WBC) counts are evident
between diseased and disease free blood samples.
Correlation analyses revealed that no correlation between
FGA, GSTP1 contents and platelet counts or WBC counts
in all four groups (HC, CR, RR and ND) (Additional file 3:
Figure S2A,B,C,D; Additional file 4: Figure S3A,B,C,D;
Additional file 5: Figure S4A,B,C,D; Additional file 6:
Figure S5A,B,C,D).
The PF4 and CTAP-III contents were found to be
decreased in patients with ND ALL (0.7506 ± 0.1003 μg/L,
599.55 ± 18.86 μg/L) and RR ALL (0.7246 ± 0.0972 μg/L,
578.31 ± 17.24 μg/L) in comparison with HCs (3.6872 ±
0.1853 μg/L, 1667.33 ± 49.36 μg/L) and CR ALL patients
(3.6496 ± 0.1669 μg/L, 1687.48 ± 50.19 μg/L) (p = 1.4595E-5,
p = 3.2170 E-5; p = 4.5269E-6, p = 3.7912 E-6). PF4 and
CTAP-III are platelet-derived chemokines. Correlation
analyses were further done between platelet counts and
PF4 contents as well as CTAP-III contents in ND ALL
patients to eliminate the influence of platelet counts onned by ROC curve. A. Area under the curve (AUC) of the peptide
UC of the peptide with MW of 2991.46 Da is 89.22%, representing
is 91%, representing higher diagnostic value. D. AUC of the peptide
E. AUC of the peptide with MW of 9288.31 Da is 90.22%, representing
Table 2 Identification results of peptides in QC model
Molecular
weight
Amino acid sequence International
Protein Index
Peptide name
2661.27 Da DEAGSEADHEGTHSTKRGHAKSRPV IPI00021885 fibrinogen alpha chain
2991.46 Da MLLADQGQSWKEEVVTVETWQEGSLK IPI00219757.13 glutathione S- transferase P1
3443.92 Da HRHPDEAAFFDTASTGKTFPGFFSPMLGEFV IPI00021885.1 isoform 1 of fibrinogen alpha
chain precursor
7764.29 Da EAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES IPI 00022446 platelet factor 4
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cients were 0.251 (p = 0.119) and 0.078 (p = 0.632), and no
correlations were found between them (Figure 10). The
contents of the two proteins had no correlation with
platelet or WBC counts in other groups (HC,CR and RR)
(Additional file 3: Figure S2E,F,G,H; Additional file 4:
Figure S3 E,F,G,H; Additional file 5: Figure S4E,F,G,H;
Additional file 6: Figure S5E,F).
ROC analyses were performed to define thresholds for
each peptide that could be used to discriminate CR and
RR patients. ROC analyses yielded cutoff values of the
serum contents of FGA (110.72 μg/L), GSTP1 (33.51 μg/L),
PF4 (2.1347 μg/L), CTAP-III (1093.04 μg/L), respectively
(Additional file 7: Figure S6).
Discussion
Published data on MRD assessment in adult ALL have
shown a strong correlation between MRD response and
outcome as well as the prognostic value of MRD reappear-
ance for hematologic relapse [9]. By using ClinProt-based
serum peptidomics, we were able to identify five differen-
tially expressed peptides (components of the QC model)
in the serum of adult ALL patients in ND group, CR
group, refractory & relapsed (RR) group and HC group.
The candidate peptides were identified as FGA, GSTP1,
isoform 1 of fibrinogen alpha chain precursor, PF4 and
CTAP-III by HPLC-MS/MS and validated by western blot
and ELISA. They were correlated with ALL therapeutic
response and the time point of ALL relapse. Thus, they
would be appropriately adapted for predicting relapse,Figure 4 MS/MS map of peptide with MW of 2661.27 Da. A. The enlarg
spectra are used to identify the peptide with MW of 2661.27 Da. C. The seqmonitoring MRD and predicting therapeutic response of
adult ALL in clinical practice.
Our QC diagnostic model composed of five peptides
had optimal distinction efficiency between ND ALL
patients and HCs. In the training set, QC model showed
a high sensitivity (100%) and specificity (96.67%). 52/54
ALL cases were correctly identified for blind validation.
The diagnostic capabilities of the five peptides, determined
by the ROC curve, were proved to be highly and
moderately accurate (AUC > 0.90 or close to 0.9). The
data suggest that the five peptides may be diagnostic
biomarkers for adult ALL. The specimen volumes
require augmentation for further validation of their clinical
diagnostic/prediction value. Moreover, functional studies of
the five peptides are necessary and conducive to ALL
pathogenesis clarification.
In recent years, mass spectrometry-based proteo-
mics technology has been applied in some researches
on hematologic malignancies, mainly including the
traditional two-dimensional gel electrophoresis (2-DE)
based separation technology combining with MALDI-
TOF-MS or Proteinchip-SELDI-TOF-MS technology. Our
study utilized MB-WCX technology for serum LWM
peptides purification, MALDI-TOF-MS technology for
mass spectra acquisition, and highly sophisticated data
mining algorithms for inspection and comparison of data
sets as well as for the discovery of complex biomarker
pattern models. Traditional 2-DE suffers from low degree
of automation, time-consuming and poor repeatability. The
target surface of protein chip has low-capacity binding sites,ed picture of peptide with MW of 2661.27 Da. B. The b and y ions
uence of the peptide with MW of 2661.27 Da.
Figure 5 MS/MS map of peptide with MW of 2991.46 Da. A. The enlarged picture of peptide with MW of 2991.46 Da. B. The b and y ions
spectra are used to identify the peptide with MW of 2991.46 Da. C. The sequence of the peptide with MW of 2991.46 Da.
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peptides. MALDI-TOF MS provides optimal performance
for m/z from 1 to 15 kDa. As the m/z increases (>15 kDa),
resolution and mass accuracy progressively decrease. In the
low m/z range(<1 kDa), there is a higher background
from ionized matrix molecules [28]. Comparing with
the other two types of beads, MB-WCX beads group
provided the best proteomic pattern, the most average
peak numbers, the highest peak intensities, and the
best capturing ability of low abundance proteins or
peptides in serum samples [29].
Our study showed that the relative intensities of the
five peptides were correlated with response of ALL.
Results were validated by western blot and ELISA.
Differences of the platelet and WBC counts are evident
between diseased and disease free blood samples. ELISA
results indicated that contents of the five peptides had no
correlation with WBC or PLT counts in ALL different
groups and HC group. Although B- and T-lineage
ALL differ significantly in their immunophenotypic,
genetic and molecular markers, no significant differences
were found between B-ALL and T-ALL in the relative
intensities of the five peptides in our study, representing
that the peptides were pan-leukemic biomarkers. These
results suggest that the peptides may be potential markers
for predicting treatment response and monitoring MRD
in adult ALL.Correlation analyses showed that relative intensities
of peptides with molecular weight of 2991.46 Da,
7764.29 Da and 9288.31 Da were correlated with time
point of ALL relapse. Adult newly diagnosed ALL patients
with very early relapse presented higher relative intensity
of peptide with molecular weight of 2991.46 Da. Relative
intensities of peptides with molecular weight of 7764.29 Da
and 9288.31 Da were lower in newly diagnosed adult ALL
patients who relapsed very early. Considering the strong
positive correlations found between peptide levels and time
of relapse, these peptides had the potential for disease
monitoring and early relapse diagnosis.
A variety of biomolecules are involved in the develop-
ment and relapse of ALL. Previously, translocation t(9;22)
(q34;q11) (Ph chromosome) with the BCR-ABL1 fusion
was found in 30% adult ALL [1]. It is conducive to imatinib
targeted therapy, predicting prognosis and monitoring
MRD for ALL. Our study showed the serum peptidomic
markers for predicting treatment response and monitoring
MRD in adult ALL. Moreover, recent papers reported that
several metabolic biomarkers of ALL from bone marrow/
plasma samples may represent an underlying metabolic
pathway associated with disease progression and relapse or
remission, such as glycerophospholipid metabolism [30],
GPEtn, GPCho [31], amino acid metabolites and derivatives
[32]. The development and relapse of ALL are multi-step
and multi-stage processes. Therefore, combining proteomic
Figure 6 MS/MS map of peptide with MW of 3443.92 Da. A. The enlarged picture of peptide with MW of 3443.92 Da. B. The b and y ions
spectra are used to identify the peptide with MW of 3443.92 Da. C. The sequence of the peptide with MW of 3443.92 Da.
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much better understanding of leukemogenesis and relapse
of ALL.
Pathogenesis and progression of ALL, as well as
response to therapies, involve a series of genetic and
epigenetic events. Versatile changes of the peptide
levels in patients’ serums may be reflection of these
genetic/epigenetic changes during disease evolvements.
And potential functions of these proteins/peptides in ALL
evolvements are waiting to be elucidated. Fibrinogen
circulates in plasma as a dimer, composed of three pairs of
unequal polypeptide chains denoted alpha chain, beta
chain and gamma chain. Extensive researches indicated
that fibrinogen was overexpressed in many malignant
tumors and could be an independent prognostic parameter
for the disease-free, distant-free and overall survival for
patients with malignancies, such as pancreatic cancer [33],
renal cell carcinoma [34], endometrial carcinoma [35,36],
cervical cancer [37], oesophageal squamous cell carcinoma
[38] and so on [39]. Fibrinogen was considered as an acute
phase reactant protein and raised in tumour progression
and increased synthesis of fibrinogen was associated with
an ongoing inflammatory response to tumor. Some studies
suggested that tumor cells could promote coagulation
process by interacting with endothelial cells and platelets,then by releasing active biological substances that activate
platelets, which lead to high level of fibrinogen in the cancer
blood. The relative intensity of FGA was increased in ND
ALL and decreased when patients received CR. When ALL
patients underwent recurrence, relative intensity of FGA
was elevated again. The results were validated by ELISA
and western blot. Relative intensities of isoform 1 of fibrino-
gen alpha chain precursor peptide fragment were opposite
to that of FGA in ALL different groups. It appears that a
large part of the human serum peptidome detected by
MALDI-TOF-MS is produced ex vivo by degradation of
endogenous substrates through endogenous proteases [40].
The peptide (2661.27 Da) identified (D605-V629) is local-
ized close to the C-terminal end of fibrinogen alpha chain
preproprotein and has a proteolytic cleavage site with a high
susceptibility to plasmin attack. However, there is no pro-
teolytic cleavage site in the identified peptide (3443.92 Da,
H511-V541). Therefore, the peptide (2661.27 Da) could be
a putative plasmin-generated proteolytic fragment and the
overexpression of FGA peptide fragment in ND-ALL was
due to a hypothetical increased enzymatic activity able to
attack the C-terminal end of FGA.
Glutathione S-transferase P1 (GSTP1), the main drug
metabolism and stress response signalling protein, can
protect cells from cytotoxic and carcinogenic agents. It
Figure 7 MS/MS map of peptide with MW of 7764.29 Da. A. The enlarged picture of peptide with MW of 7764.29 Da. B. The b and y ions
spectra are used to identify the peptide with MW of 7764.29 Da. C. The sequence of the peptide with MW of 7764.29 Da.
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and poor clinical prognosis of tumors. GSTP1 was
upregulated in a variety of tumors [41-43]. Apart from
aberrant protein expression levels, attention has been
directed toward the association of GSTP1 polymorphisms
with the risk of cancers [44-47]. GSTP1 was found to be
involved in the drug resistance, and inhibition of GSTP1Table 3 Relative intensity of peptides in the QC model in diff
Mass Ave1 ± StdDev1 Ave2 ± StdDev2 Ave3 ± Std
2661.27 28.39 ± 22.56 7.44 ± 3.69 7.76 ± 3.48
2991.46 17.24 ± 8.54 1.96 ± 0.63 1.63 ± 0.52
3443.92 1.54 ± 0.66 2.64 ± 0.9 2.62 ± 0.86
7764.29 1.39 ± 0.7 2.68 ± 1.44 2.71 ± 1.45
9288.31 1.31 ± 0.28 3.63 ± 1.87 3.9 ± 1.66
Class1: ALL ND group; Class2: HC group; Class3: ALL CR group; Class4: ALL RR group
n: Case number.expression could reverse the drug resistance and induce
tumour cell apoptosis [48,49]. The study of GSTP1 genetic
polymorphisms in pediatric ALL showed that GSTP1
genotype was unrelated to genetic susceptibility of ALL,
but GSTP1*V105 was involved in ALL relapse [50]. Studies
suggested that the GSTP1Val/Val genotype might be
considered as risk genotype for developing ALL anderent ALL groups
Dev3 Ave4 ± StdDev4 n1 n2 n3 n4





; Mass: Molecular weight; Ave: Average peak intensity; Std: Standard deviation;
Figure 8 (See legend on next page.)
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Figure 8 Impact of the relative intensities of five peptides on relapse. A. No correlation was found between relative intensity of peptide m/z
2661.27 and ALL relapse time after initial diagnosis. B. Newly diagnosed ALL patients with higher relative intensity of peptide m/z 2991.46 relapsed
earlier than those with lower relative intensity. C. No correlation was found between relative intensity of peptide m/z 3443.92 and ALL relapse time
after initial diagnosis. D. Newly diagnosed ALL patients with lower relative intensity of peptide m/z 7764.29 had a significantly earlier relapse. E. Lower
relative intensity of peptide m/z 9288.31 in newly diagnosed ALL patients was associated with an earlier relapse.
Bai et al. Proteome Science 2014, 12:49 Page 12 of 17
http://www.proteomesci.com/content/12/1/49was correlated with poor prognosis [51]. Our research
showed that a positive correlation existed between
GSTP1 level and ALL treatment response and newly
diagnosed ALL patients with higher relative intensity
of GSTP1 peptide were prone to an earlier relapse. It
is speculated that GSTP1 may play an important role
in ALL progression and chemotherapy resistance. The
specific mechanism and genetic polymorphism of GSTP1
in adult ALL need further study.
PF4 and CTAP-III are two platelet-associated chemokines
that modulate tumor angiogenesis, inflammation within the
tumor microenvironment, and tumor growth. Vermeulen
found that average levels of PF4 and CTAP-III were
down-regulated in the serum of benzene-exposed
workers in comparison with control subjects [27]. Several
proteomic studies revealed that PF4 and CTAP-III were
decreased in acute leukemia and MDS comparing
with HCs [18,25,52,53]. Our study showed that relative
intensities of PF4 and CTAP-III were negatively cor-
related with adult ALL response. Moreover, newlyFigure 9 Validation of proteins by immunoblotting. A. Levels of the FG
groups and normal cells. Weak PF4 immunoreactive bands are seen in new
comparison of FGA protein relative to β-actin as determined by western bl
relative to β-actin as determined by western blot analysis in figure A. D. De
by western blot analysis in figure A. (FGA: fibrinogen alpha chain; GSTP1: g
remission; ALL-ND: ALL newly diagnosed; ALL-RR: ALL refractory & relapseddiagnosed ALL patients with lower relative intensities
of PF4 and CTAP-III were prone to an earlier relapse.
By immunoblotting, PF4 protein was significantly decreased
in ND and RR ALL cells. The serum PF4 content was
correlated with treatment response. These findings are
consistent with Kim’s study [53]. PF4 and CTAP-III are
platelet-derived chemokines, whereas there were always
reduced platelets and WBC counts in hematologic
malignancies. Previous studies revealed that lower PF4
expression was not due to thrombocytopenia. Our
ELISA results demonstrated that no differences were
found in serum PF4 and CTAP-III contents between
ALL with and without reduced platelets/WBC counts.
Linear regression analyses showed no correlation between
PF4/CTAP-III contents and platelet or WBC counts. It
follows that the reduction of serum PF4 and CTAP-III
contents in ND ALL are not due to thrombocytopenia
and hypoleucocytosis. PF4 is a major antiangiogenic
factor. We found that PF4 was downregulated in ND and
RR ALL, which may indicate that the antiangiogenicA and GSTP1 protein differ among the leukemia cells in distinct ALL
ly diagnosed and refractory & relapsed ALL cases. B. Densitometry
ot analysis in figure A. C. Densitometry comparison of GSTP1 protein
nsitometry comparison of PF4 protein relative to β-actin as determined
lutathione S-transferase P1; PF4: platelet factor 4; ALL- CR: ALL complete
).
Figure 10 Correlation analyses between serum PF4/CTAP-III contents and platelet counts in newly diagnosed ALL. Linear regression
analyses show that no correlations are found between PF4 (A)/CTAP-III (B) contents and platelet counts.
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http://www.proteomesci.com/content/12/1/49activity of PF4 was compromised in these patients. Loss of
anti-angiogenesis activity and the resultant imbalance
between pro- and anti-angiogenesis may contribute to in-
creased proliferation and infiltration of ALL cells.
This is probably one of the reasons why PF4 expression is
negatively associated with clinical outcome of ALL.
Conclusions
In conclusion, the ALL QC model constructed by
application of ClinProt system had a high sensitivity
and specificity to discriminate between ALL patients
and healthy controls. The relative intensities of the
peptides in the QC model were correlated with ALL
treatment response and time point of relapse. These
findings were validated by ELISA and western-blot. We
speculate these peptides, such as fibrinogen alpha chain,
isoform 1 of fibrinogen alpha chain precursor and gluta-
thione S-transferase P1, platelet factor 4, connective tissue
active peptide III can be used as potential markers for pre-
dicting relapse, assessing treatment response and monitor-
ing minimal residual disease in adult ALL.
Methods
Study population
This study was approved by Ethics Committee of the
Second Affiliated Hospital of Medical School of Xi’an
Jiaotong University. 84 serum samples were collected
from adult ND ALL patients who had been confirmed
by lymphocytic cytological diagnosis based on the FAB
classification system in the Second Affiliated Hospital of
Xi’an Jiaotong University during a given period of time
(2009.12–2012.8). At the same time, 84 healthy control
serum samples were collected from adults who tookhealth examinations and had not been diagnosed with
any disease. In addition, 44 serum samples from ALL pa-
tients with hematologic CR and 45 serum samples from
RR ALL patients were obtained (details in Table 4). 45
RR ALL patients consisted of 39 early relapse patients
and 6 refractory patients. The response criteria of ALL were
set according to the definition of response in adult ALL
[54,55]. The CR and RR serum samples in our study were
taken at d28 from initiation of post-induction therapy. The
ND adult ALL patients were treated with VDP (Vinorelbine
25-30 mg/m2, iv, d1, 8, 15, 22; Pirarubicin 20-25 mg/m2,
iv, d1, 2, 3; Prednisone 60 mg/m2, po, d1-28), VDLP
(Vinorelbine 25-30 mg/m2, iv, d1, 8, 15, 22; Pirarubicin
20-25 mg/m2, iv, d1, 8, 15, 22; L-Asparaginase 10000U, iv,
d17-28; Prednisone 60 mg/m2, po, d1-28). Ph (+) ALL
patients also received oral imatinib (400-600 mg/d). All
donors obtained informed consents.
Serum peptides purification
Serum samples were collected according to standard proto-
col. Fasting blood samples were collected from patients in
the morning and allowed to clot at room temperature for
2 h. Sera were then separated by centrifugation at
2500 rpm for 10 min and stored at -80°C until analysis. The
length of cryopreservation period for each serum sample
was less than 6 months. For the reproducibility experi-
ments, serum from each ALL patient and each HC were
processed using the same MALDI-TOF-MS instrument to
run three within-run assays and three between-run assays.
MB-WCX beads kit was purchased from Bruker
Daltonics Inc. (Billerica, MA · USA) and used to extract
serum peptides. All purifications were performed in a one-
step procedure according to manufacturers’ instructions
Table 4 Clinical features of patients in different ALL groups before chemotherapy
Clinical features ALL
Newly Diagnosed CR Refractory & Relapsed
Sex
Male 50 24 26
Female 34 20 19
Age (year) 31 (18-77) 29 (18-62) 27 (18-77)
WBC (×109/L) 53 (0.9-367.4) 14.75 (3.01-39.65) 25.99 (0.45-102.56)
Hb (g/L) 70 (31-143) 108 (84-394) 75 (48-139)
PLT(×109/L) 37(1-338) 105 (25-394) 45 (2-245)
Subtype T 14 T 4 T 4
B 70 B 40 B 41
Chromosome Abnormality Ph + 20 Ph + 6 Ph + 10
del (5) (p14) 2 21 +mar 1 del (5) (p14) 1
21 +mar 2
Molecular Genetics Abnormality bcr-abl 20 bcr-abl 6 bcr-abl 10
Sternal tenderness 54/84 20/44 27/45
Lymphadenectasis 50/84 25/44 26/45
Splenohepatomegalia 45/84 21/44 23/45
Curative effect 69/84 44/44 36/45
This table shows clinical features of ALL patients in different groups at the time of diagnosis. WBC: White blood cell; Hb: Hemoglobin; PLT: Platelet. Curative effect
refers to achieving complete remission after 2 courses of standard chemotherapy.
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Detail operation steps were done as previously described
[25]. Briefly, first, 10 μL beads, 10 μL binding solution (BS)
and 5 μL serum samples were mixed by pipetting in a
200 μL Orcugen sample tube and incubated for 5 min. The
tube was then placed on a magnetic bead separation
device for 1 min to collect the beads on the tube
wall. The supernatant was removed and 100 μL MB
washing solution (WS) was added and mixed thoroughly
with the beads. After washing three times, the supernatant
was removed and 5 μL MB eluting solution (ES) was
added. The beads were collected on the tube wall in
the separation device for 2 min. Finally, the clarified
supernatant was transferred to a fresh tube with 5 μl
stabilization buffer (SB) and stored at −20°C.
Data acquisition by MALDI-TOF-MS
1) 1 μL eluted sample was spotted onto a MALDI-TOF
AnchorChipTM target (600 μm anchor diameter) and
air-drying at room temperature, then 1 μL matrix
(0.3 mg/ml HCCA, 50% ACN, 2% TFA) was spotted
onto MALDI-TOF AnchorChip target. 2) AnchorChip
target was placed into the Microflex mass spectrom-
eter (Bruker Daltonics). 3) Samples were detected
after calibration of the instrument by ClinProt stand-
ard, scan range was 1-l0KD. FlexControl2.2 software
was applied to data acquisition and peptide profilingswere gained constituted by different mass to charge
ratios (m/z).
Data processing and statistical analysis
Original mass spectra were normalized by Flexanalysis3.0
software, including smoothing and substrate baseline.
Thereafter, we selected statistical algorithm built-in
Clinprotools2.2 software for statistical analyses and
acquired different expressed peptides. Wilcoxon rank
sum test was performed to compare relative intensities
differences of peptide peaks between newly diagnosed
ALL and healthy controls. Statistical significance was
defined as p < 0.05. Relative intensity differences of
the peptide peaks in each group were analysed by
Kruskal-Wallis rank sum test. For multiple comparisons
among the four groups, significant level was adjusted to
0.0083(0.05/4(4-1)/2). Statistical significance was defined
as p < 0.0083. GA, SNN and QC algorithm were applied
to establish diagnostic model for distinguishing ALL from
HCs. Correlation analysis was used for linear regression
analysis. ROC analyses were performed to calculate AUCs
to define threshold for each peptide that could be used to
discriminate CR and RR patients.
Identification of peptide biomarkers
Nano-LC/ESI-MS/MS system consisting of an Aquity
UPLC system (Waters Corporation, Milford, USA) and a
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Waltham, MA, USA) equipped with a nano-ESI source
(Michrom Bioresources, Auburn, USA) was utilized to
perform peptide sequencing and identification. The peptide
solutions purified by magnetic beads, were loaded to a C18
trap column (nanoACQUITY) (180 μm×20 mm× 5 μm
(symmetry)). The flow rate was 15 μl/min. Then the
desalted peptides were analyzed by C18 analytical column
(nanoACQUITY) (75 μm×150 mm× 3.5 μm (symmetry))
at a flow rate of 400 nl/min for 60 min. The mobile
phases A (5% acetonitrile, 0.1% formic acid) and B
(95% acetonitrile, 0.1% formic acid) were used for
analytical columns. The gradient elution profile was
as follows: 5%B–45%B–80%B –80%B–5%B–5%B in
60 min. The spray voltage was 1.8 kV. MS scan time was
60 min. Experimental mode were data dependent and
dynamic exclusion, scilicet MS/MS spectra were lim-
ited to two consecutive scans per precursor ion
within 10 s followed by 90 s of dynamic exclusion.
Mass scan range was from m/z 400 to 2000. MS scan used
Obitrap, resolution was set at 100000. CID and MS/MS
scan employed LTQ. In MS spectrogram, we selected sin-
gle isotope composed of 10 ions with strongest inten-
sity as parent ion for MS/MS. Single charge was
excluded and not as parent ion. We applied data
analysis software Bioworks Browser 3.3.1 SP1 for
Sequest™ retrieving. Retrieval Database was Inter-
national Protein Index (IPI human v3.45 fasta with
71983 entries). Parent ion error and fragment ions
error were set at 100 ppm and 1 Da, respectively. Digested
mode was non-digested and variable modification was
methionine oxidation.
Western blot analysis for validation
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting were performed essen-
tially as described elsewhere [56]. Briefly, cell pellets were
resuspended on ice in lysis buffer containing 10 mM
Tris-HCl (pH 7.4), 5 mM MgCl2, 1% Triton X-100,
100 mM NaCl, 10 mM NaF, 1 mM Na3VO4 and a
protease inhibitor cocktail. After sonication, cellular
proteins were separated on an SDS-polyacrylamide gel
and transferred to polyvinylidene fluoride membranes
(Roche Diagnostics Corporation, Indianapolis, Indiana
United States), which were probed with the appropriate
primary antibodies. Immunoreactivity was detected with
the relevant horseradish peroxidase-labeled secondary anti-
bodies which, in turn, were visualized on an Image Reader
Tano-5500 (Tano, Shanghai, China) using chemilumines-
cence substrate reagent purchased from 7 sea pharmtech
(Shanghai, China). For quantification of the data, the
images were further analyzed on the same instrument
using 2D Densitometry Image Analyzer IPP 7.0 software
(Tano, Shanghai, China).ELISA determination of serum proteins
Serum contents of FGA, GSTP1, PF4 and CTAP-III
were assayed by ELISA and compared in 40 ND, 40 CR,
40 RR ALL patients and 40 HCs. Detailed procedures
were according to manufacturers’ instructions of ELISA
kit (R&D, USA). Furthermore, we analyzed the correlation
of serum protein contents and platelet as well as WBC
counts in different ALL patients and HCs. SNK-q test was
done through the statistical software SPSS17.0. For
multiple comparisons among the four groups, significant
level was adjusted to 0.0083(0.05/4(4-1)/2). Correlation ana-
lysis used linear regression analysis. Statistical significance
was defined as p < 0.05.Additional files
Additional file 1: Figure S1. ROC curves of the relative intensities of
peptides differentiating patients with CR from RR. A. Area under the
curve (AUC) of the peptide with MW of 2661.27 Da is 92.3%, representing
higher diagnostic value for distinguishing CR from RR patients. B. AUC of
the peptide with MW of 2991.46 Da is 100%, representing higher
diagnostic value for distinguishing CR from RR patients. C. AUC of the
peptide with MW of 3443.92 Da is 91%, representing higher diagnostic
value for distinguishing CR from RR patients. D. AUC of the peptide with
MW of 7764.29 Da is 89.5%, representing moderate diagnostic value for
distinguishing CR from RR patients. E. AUC of the peptide with MW of
9288.31 Da is 98.7%, representing higher diagnostic value for
distinguishing CR from RR patients.
Additional file 2: Table S1. RI of peptides with respect to the clinical
characteristics at diagnosis.
Additional file 3: Figure S2. Correlation analyses between contents of
serum peptides and platelet/WBC counts in healthy control group. A.
Correlation coefficient of FGA contents and platelet counts is 0.044 (p = 0.787).
B. Correlation coefficient of FGA contents and WBC counts is 0.027 (p = 0.869).
C. Correlation coefficient of GSTP1 contents and platelet counts is 0.191
(p = 0.238). D. Correlation coefficient of GSTP1 contents and WBC counts is
0.079 (p = 0.630). E. Correlation coefficient of PF4 contents and platelet counts
is 0.171 (p = 0.292). F. Correlation coefficient of PF4 contents and WBC counts
is 0.139 (p = 0.394). G. Correlation coefficient of CTAP-III contents and platelet
counts is 0.033 (p = 0.838). H. Correlation coefficient of CTAP-III contents and
WBC counts is 0.070 (p = 0.669). (FGA: fibrinogen alpha chain; GSTP1:
glutathione S-transferase P1; PF4: platelet factor 4; CTAP-III: connective tissue
active peptide III; WBC: white blood cell).
Additional file 4: Figure S3. Correlation analyses between contents of
serum peptides and platelet/WBC counts in ALL complete remission
group. A. Correlation coefficient of FGA contents and platelet counts is
0.097 (p = 0.552). B. Correlation coefficient of FGA contents and WBC
counts is 0.097 (p = 0.552). C. Correlation coefficient of GSTP1 contents
and platelet counts is 0.126 (p = 0.440). D. Correlation coefficient of
GSTP1 contents and WBC counts is 0.185 (p = 0.254). E. Correlation
coefficient of PF4 contents and platelet counts is 0.157 (p = 0.333). F.
Correlation coefficient of PF4 contents and WBC counts is 0.236
(p = 0.143). G. Correlation coefficient of CTAP-III contents and platelet
counts is 0.146 (p = 0.369). H. Correlation coefficient of CTAP-III contents
and WBC counts is 0.128 (p = 0.431). (FGA: fibrinogen alpha chain; GSTP1:
glutathione S-transferase P1; PF4: platelet factor 4; CTAP-III: connective
tissue active peptide III; WBC: white blood cell).
Additional file 5: Figure S4. Correlation analyses between contents of
serum peptides and platelet/WBC counts in ALL refractory&relapsed
group. A. Correlation coefficient of FGA contents and platelet counts is
0.043 (p = 0.792). B. Correlation coefficient of FGA contents and WBC
counts is 0.057 (p = 0.728). C. Correlation coefficient of GSTP1 contents
and platelet counts is 0.086 (p = 0.596). D. Correlation coefficient of
GSTP1 contents and WBC counts is 0.054 (p = 0.741).E. Correlation
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Correlation coefficient of PF4 contents and WBC counts is 0.102 (p = 0.529).
G. Correlation coefficient of CTAP-III contents and platelet counts is 0.079
(p = 0.627). H. Correlation coefficient of CTAP-III contents and WBC counts
is 0.012 (p = 0.941). (FGA: fibrinogen alpha chain; GSTP1: glutathione
S-transferase P1; PF4: platelet factor 4; CTAP-III: connective tissue active
peptide III; WBC: white blood cell).
Additional file 6: Figure S5. Correlation analyses between contents of
serum peptides and platelet/WBC counts in ALL newly diagnosed group.
A. Correlation coefficient of FGA contents and platelet counts is 0.253
(p = 0.115). B. Correlation coefficient of FGA contents and WBC counts is
0.244 (p = 0.129). C. Correlation coefficient of GSTP1 contents and platelet
counts is 0.207 (p = 0.200). D. Correlation coefficient of GSTP1 contents
and WBC counts is 0.118 (p = 0.468). E. Correlation coefficient of PF4
contents and WBC counts is 0.178 (p = 0.271). F. Correlation coefficient of
CTAP-III contents and WBC counts is 0.148 (p = 0.361). (FGA: fibrinogen
alpha chain; GSTP1: glutathione S-transferase P1; PF4: platelet factor 4;
CTAP-III: connective tissue active peptide III; WBC: white blood cell).
Additional file 7: Figure S6. ROC curves of the serum contents of
proteins differentiating patients with CR from RR. A. Area under the curve
(AUC) of FGA is 99.6%. B .AUC of GSTP1 is 99.4%. C. AUC of PF4 is 99.8%. D.
AUC of CATP-III is 99.8%. AUCs of the four proteins are all ≥90%, representing
higher diagnostic values of the serum contents of the four proteins for
distinguishing CR from RR patients. (FGA: fibrinogen alpha chain; GSTP1:
glutathione S-transferase P1; PF4: platelet factor 4; CTAP-III: connective tissue
active peptide III).
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